These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2829488)

  • 1. Cytobiological studies in multiple myeloma.
    Pileri A; Massaia M; Dianzani U; Omedè P; Boccadoro M
    Acta Haematol; 1987; 78 Suppl 1():41-2. PubMed ID: 2829488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics.
    Massaia M; Ma DD; Boccadoro M; Golzio F; Gavarotti P; Dianzani U; Pileri A
    Blood; 1985 Mar; 65(3):530-4. PubMed ID: 2982438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.
    Massaia M; Dianzani U; Pioppo P; Sibilla E; Boccadoro M; Pileri A
    Clin Exp Immunol; 1987 Aug; 69(2):426-32. PubMed ID: 2820641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
    Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
    Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
    Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
    Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2+/T8+ lymphocytes.
    Dianzani U; Massaia M; Pileri A; Grossi CE; Clement LT
    J Immunol; 1986 Jul; 137(2):484-9. PubMed ID: 3013991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
    Boccadoro M; Gallamini A; Fruttero A; Gavarotti P; Redoglia V; Buffa F; Ruá S; Pileri A
    J Clin Oncol; 1985 Nov; 3(11):1503-7. PubMed ID: 4056842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5'nucleotidase deficiency.
    Massaia M; Dianzani U; Pioppo P; Boccadoro M; Redoglia V; Omede P; Pileri A
    J Clin Lab Immunol; 1988 Jun; 26(2):89-95. PubMed ID: 2848130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
    Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
    Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders.
    Garewal H; Durie BG; Kyle RA; Finley P; Bower B; Serokman R
    J Clin Oncol; 1984 Jan; 2(1):51-7. PubMed ID: 6366146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance.
    Patriarca F; Fanin R; Silvestri F; Candoni A; Zaja F; Sperotto A; Geromin A; Baccarani M
    Leuk Lymphoma; 1999 Aug; 34(5-6):591-6. PubMed ID: 10492084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
    Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
    Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased 5' nucleotidase activity in lymphocytes from asymptomatic sexually active homosexual men and patients with the acquired immune deficiency syndrome.
    Murray JL; Reuben JM; Munn CG; Mansell PW; Newell GR; Hersh EM
    Blood; 1984 Nov; 64(5):1016-21. PubMed ID: 6091811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
    Dutoit JC; Vanderkerken MA; Verstraete KL
    Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
    Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
    Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.